Home › NCT07760896
The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Age 18 years or older. Able to speak, read, and understand English. Interested in supporting physical and emotional well-being. Access to a reliable Internet-enabled device, such as a computer, smartphone, or tablet. Possess basic skills needed to complete online study forms. Currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner. Report that the medication was prescribed for an FDA-approved indication, such as type 2 diabetes mellitus, chronic weight management for obesity or overweight with at least one weight-related condition, moderate-to-severe obstructive sleep apnea in adults with obesity, or another FDA-approved cardiometabolic indication. Willing to complete online consent, registration, program measures, and daily tracking forms. Willing to participate in the 30-day WILD 5 Wellness program delivered as part of the GLOW Study. \- Exclusion Criteria: Under 18 years of age. Unable to speak, read, or understand English. Do not have access to a reliable Internet-enabled device. Do not possess basic skills needed to complete online study forms. Not currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner. Report that the medication was not prescribed for an FDA-approved indication. Pregnant or planning to become pregnant in the next 30 days. Currently have thoughts about harming themselves or someone else. Currently experiencing symptoms suggestive of active psychosis. Unwilling or unable to complete the required online study forms or participate in the 30-day \-
About the study
The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment.
The main questions it aims to answer are:
1. Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program? 2. Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?
Participants will:
1. Complete online questionnaires before and after the program. 2. Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition. 3. Complete a brief online tracking form each day during the 30-day program.
What is being tested
- WILD 5 Wellness Program (behavioral)
Sponsor: Saundra Jain · Participants: 200 · Started: Sep 15, 2026
Contact the study team
- Saundra Jain, MA, PsyD, LPC · Phone: 888-252-7806
Official record on ClinicalTrials.gov — NCT07760896
Locations in the U.S.
| Texas | The GLOW Study, The Colony |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.